BeOne Medicines (BEIGF) Notes Payables (2017 - 2025)

BeOne Medicines (BEIGF) reported Notes Payables of $813.3 million for Q3 2025, down 4.49% quarter-over-quarter from $851.5 million in Q4 2024.

BeOne Medicines (BEIGF) Notes Payables (2017 - 2025) Analysis & Trends

BeOne Medicines (BEIGF) has 4 years of Notes Payables data on file, last reported at $813.3 million in Q3 2025.

Notes Payables for Q3 2025 came in at $813.3 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $813.3 million (changed N/A YoY), and the FY2024 annual result was $851.5 million, changed N/A from the prior year.
Notes Payables retreated to $813.3 million in Q3 2025 per BEIGF's latest filing, from $851.5 million in the prior quarter.
Over five years, Notes Payables peaked at $851.5 million in Q4 2024 and troughed at $813.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	821,726.73 Bn	821,726.69 Bn	-
2	Belite Bio	57,768.00 Bn	57,768.00 Bn	-
3	Quantum Biopharma	16,655.88 Bn	16,655.88 Bn	-
4	Legend Biotech	3,540.00 Bn	3,539.71 Bn	242.10 Mn
5	Evaxion A	1,526.26 Bn	1,526.24 Bn	-
6	Akari Therapeutics	1,520.09 Bn	1,520.09 Bn	-
7	Psyence Biomedical	223.87 Bn	223.87 Bn	-
8	Vertex Pharmaceuticals	114.47 Bn	107.23 Bn	2.59 Bn
9	Abivax	91.22 Bn	91.22 Bn	-
10	BeOne Medicines	-	-	1.35 Bn

Download Data